Natasha K Wolfe1, Joshua D Mitchell1, David L Brown1. 1. Department of Medicine, Cardiovascular Division, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8086, St. Louis, MO 63110, USA.
Abstract
AIMS: Guideline-directed medical therapy (GDMT) is underutilized in patients with coronary artery disease (CAD). However, there are no studies evaluating the impact of GDMT adherence on mortality among patients with CAD and heart failure with reduced ejection fraction (HFrEF). We sought to investigate the association of GDMT adherence with long-term mortality in patients with CAD and HFrEF. METHODS AND RESULTS: Surgical Treatment for Ischaemic Heart Failure (STICH) was a trial of patients with an left ventricular ejection fraction ≤35% and CAD amenable to coronary artery bypass graft surgery (CABG) who were randomized to CABG plus medical therapy (N = 610) or medical therapy alone (N = 602). Median follow-up time was 9.8 years. We defined GDMT for the treatment of CAD and HFrEF as the combination of at least one antiplatelet drug, a statin, a beta-blocker, and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was all-cause mortality. Assessment of the independent association between GDMT and mortality was performed using multivariable Cox regression with GDMT as a time-dependent covariate. In the CABG arm, 63.6% of patients were on GDMT throughout the study period compared to 66.5% of patients in the medical therapy arm (P = 0.3). GDMT was independently associated with a significant reduction in mortality (hazard ratio 0.65, 95% confidence interval 0.56-0.76; P < 0.001). CONCLUSION: GDMT is associated with reduced mortality in patients with CAD and HFrEF independent of revascularization with CABG. Strategies to improve GDMT adherence in this population are needed to maximize survival. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Guideline-directed medical therapy (GDMT) is underutilized in patients with coronary artery disease (CAD). However, there are no studies evaluating the impact of GDMT adherence on mortality among patients with CAD and heart failure with reduced ejection fraction (HFrEF). We sought to investigate the association of GDMT adherence with long-term mortality in patients with CAD and HFrEF. METHODS AND RESULTS: Surgical Treatment for Ischaemic Heart Failure (STICH) was a trial of patients with an left ventricular ejection fraction ≤35% and CAD amenable to coronary artery bypass graft surgery (CABG) who were randomized to CABG plus medical therapy (N = 610) or medical therapy alone (N = 602). Median follow-up time was 9.8 years. We defined GDMT for the treatment of CAD and HFrEF as the combination of at least one antiplatelet drug, a statin, a beta-blocker, and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was all-cause mortality. Assessment of the independent association between GDMT and mortality was performed using multivariable Cox regression with GDMT as a time-dependent covariate. In the CABG arm, 63.6% of patients were on GDMT throughout the study period compared to 66.5% of patients in the medical therapy arm (P = 0.3). GDMT was independently associated with a significant reduction in mortality (hazard ratio 0.65, 95% confidence interval 0.56-0.76; P < 0.001). CONCLUSION: GDMT is associated with reduced mortality in patients with CAD and HFrEF independent of revascularization with CABG. Strategies to improve GDMT adherence in this population are needed to maximize survival. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen Journal: Transl Behav Med Date: 2015-07-09 Impact factor: 3.046
Authors: L Kristin Newby; Nancy M Allen LaPointe; Anita Y Chen; Judith M Kramer; Bradley G Hammill; Elizabeth R DeLong; Lawrence H Muhlbaier; Robert M Califf Journal: Circulation Date: 2006-01-09 Impact factor: 29.690
Authors: Niteesh K Choudhry; Amanda R Patrick; Elliott M Antman; Jerry Avorn; William H Shrank Journal: Circulation Date: 2008-02-19 Impact factor: 29.690
Authors: Juhani Knuuti; William Wijns; Antti Saraste; Davide Capodanno; Emanuele Barbato; Christian Funck-Brentano; Eva Prescott; Robert F Storey; Christi Deaton; Thomas Cuisset; Stefan Agewall; Kenneth Dickstein; Thor Edvardsen; Javier Escaned; Bernard J Gersh; Pavel Svitil; Martine Gilard; David Hasdai; Robert Hatala; Felix Mahfoud; Josep Masip; Claudio Muneretto; Marco Valgimigli; Stephan Achenbach; Jeroen J Bax Journal: Eur Heart J Date: 2020-01-14 Impact factor: 29.983
Authors: William B Borden; Rita F Redberg; Alvin I Mushlin; David Dai; Lisa A Kaltenbach; John A Spertus Journal: JAMA Date: 2011-05-11 Impact factor: 56.272
Authors: Edmond L Toy; Nicolas U Beaulieu; Joshua M McHale; Timothy R Welland; Craig A Plauschinat; Andrine Swensen; Mei Sheng Duh Journal: Respir Med Date: 2010-09-29 Impact factor: 3.415
Authors: William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Javaid Iqbal; Yao-Jun Zhang; David R Holmes; Marie-Claude Morice; Michael J Mack; Arie Pieter Kappetein; Ted Feldman; Elizabeth Stahle; Javier Escaned; Adrian P Banning; Julian P Gunn; Antonio Colombo; Ewout W Steyerberg; Friedrich W Mohr; Patrick W Serruys Journal: Circulation Date: 2015-02-24 Impact factor: 29.690
Authors: David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: Loren F Hiratzka; Kim A Eagle; Li Liang; Gregg C Fonarow; Kenneth A LaBresh; Eric D Peterson Journal: Circulation Date: 2007-09-11 Impact factor: 29.690
Authors: Safiya Al-Aghbari; Juhaina Salim Al-Maqbali; Abdullah M Al Alawi; Mohammed Al Za'abi; Ibrahim Al-Zakwani Journal: Pharm Pract (Granada) Date: 2022-04-13